TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2018-05-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out if erlotinib given with chemotherapy
and radiation therapy can help to control NSCLC. The safety of this combination treatment
will also be studied.
Researchers will also test the tissue from your earlier biopsy to measure the levels of
epidermal growth factor receptor (EGFR). The purpose of EGFR testing is to learn about any
link between various forms of EGFR and your response to treatment with erlotinib.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Genentech, Inc. United States Department of Defense